Evidence map›Paper›PMID 36151530›Full record

ArticleBMC musculoskeletal disorders2022

Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis.

Mayura Shinde, Carla Rodriguez-Watson, Tancy C Zhang, David S Carrell, Aaron B Mendelsohn, Young Hee Nam, Amanda Carruth, Kenneth R Petronis, Cheryl N McMahill-Walraven, Aziza Jamal-Allial and 8 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC musculoskeletal disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

Mayura ShindeHarvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA. mayura_shinde@harvardpilgrim.org.
Carla Rodriguez-WatsonReagan-Udall Foundation for the Food and Drug Administration, Washington, DC, USA.
Tancy C ZhangHarvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA.
David S CarrellKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Aaron B MendelsohnHarvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA.
Young Hee NamHarvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA.
Amanda CarruthHarvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA.
Kenneth R PetronisPfizer Inc, New York, NY, USA.
Cheryl N McMahill-WalravenCVS Health Clinical Trial Services (Formerly Known As Healthagen), Blue Bell, PA, USA.
Aziza Jamal-AllialHealthCore, Inc, Watertown, MA, USA.
Vinit NairHumana Healthcare Research Inc, Louisville, KY, USA.
Pamala A PawloskiHealthPartners, Bloomington, MN, USA.
Anne HickmanPfizer Inc, Groton, CT, USA.
Mark T BrownPfizer Inc, Groton, CT, USA.
Jennie FrancisEli Lilly and Company, Indianapolis, IN, USA.
Ken HornbuckleEli Lilly and Company, Indianapolis, IN, USA.
Jeffrey S BrownHarvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA.
Jingping MoPfizer Inc, New York, NY, USA.
Harvard Pilgrim Health Care · USPfizer (United States) · USEli Lilly (United States) · USHarvard University · USCVS Health (United States) · USHealthPartners · USKaiser Permanente Washington Health Research Institute · USReagan-Udall Foundation · USUniversity of Kentucky HealthCare · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently available medications for chronic osteoarthritis pain are only moderately effective, and their use is limited in many patients because of serious adverse effects and contraindications. The primary surgical option for osteoarthritis is total joint replacement (TJR). The objectives of this study were to describe the treatment history of patients with osteoarthritis receiving prescription pain medications and/or intra-articular corticosteroid injections, and to estimate the incidence of TJR in these patients.

methodsThis retrospective, multicenter, cohort study utilized health plan administrative claims data (January 1, 2013, through December 31, 2019) of adult patients with osteoarthritis in the Innovation in Medical Evidence Development and Surveillance Distributed Database, a subset of the US FDA Sentinel Distributed Database. Patients were analyzed in two cohorts: those with prevalent use of "any pain medication" (prescription non-steroidal anti-inflammatory drugs [NSAIDs], opioids, and/or intra-articular corticosteroid injections) using only the first qualifying dispensing (index date); and those with prevalent use of "each specific pain medication class" with all qualifying treatment episodes identified.

resultsAmong 1 992 670 prevalent users of "any pain medication", pain medications prescribed on the index date were NSAIDs (596 624 [29.9%] patients), opioids (1 161 806 [58.3%]), and intra-articular corticosteroids (323 459 [16.2%]). Further, 92 026 patients received multiple pain medications on the index date, including 71 632 (3.6%) receiving both NSAIDs and opioids. Altogether, 20.6% of patients used an NSAID at any time following an opioid index dispensing and 17.2% used an opioid following an NSAID index dispensing. The TJR incidence rates per 100 person-years (95% confidence interval [CI]) were 3.21 (95% CI: 3.20-3.23) in the "any pain medication" user cohort, and among those receiving "each specific pain medication class" were NSAIDs, 4.63 (95% CI: 4.58-4.67); opioids, 7.45 (95% CI: 7.40-7.49); and intra-articular corticosteroids, 8.05 (95% CI: 7.97-8.13).

conclusionsIn patients treated with prescription medications for osteoarthritis pain, opioids were more commonly prescribed at index than NSAIDs and intra-articular corticosteroid injections. Of the pain medication classes examined, the incidence of TJR was highest in patients receiving intra-articular corticosteroids and lowest in patients receiving NSAIDs.

Indexed as

Arthroplasty, ReplacementChronic PainOsteoarthritisAdrenal Cortex HormonesAdultAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalCohort StudiesHumansIncidenceRetrospective StudiesAdrenal Cortex HormonesAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalAdministrative claims dataOsteoarthritisPain medicationsTotal joint replacementTreatment patternsUS FDA Sentinel Distributed Database

Identifiers

PMID36151530
PMCPMC9502954
OpenAlexW4297001207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.